[{"address1": "One Cavendish Place", "address2": "4th Floor", "city": "London", "zip": "W1G 0QF", "country": "United Kingdom", "phone": "44 33 3023 7300", "website": "https://www.mereobiopharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 33, "companyOfficers": [{"maxAge": 1, "name": "Dr. Denise Vera Scots-Knight Ph.D.", "age": 65, "title": "Co-Founder, CEO & Executive Director", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 890562, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles Edward Sermon", "age": 55, "title": "Co-Founder, General Counsel, Business Development & Company Secretary", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 625786, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christine  Fox CPA", "age": 43, "title": "Chief Financial Officer", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 569768, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John P. Richard M.B.A.", "age": 67, "title": "Co-Founder & Chief Business Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John A. Lewicki Ph.D.", "age": 72, "title": "Chief Scientific Officer", "yearBorn": 1952, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jackie  Parkin", "age": 66, "title": "Senior VP & Therapeutic Head", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alexandra  Hughes-Wilson", "age": 53, "title": "Chief of Patient Access & Commercial Planning", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Suba  Krishnan", "age": 59, "title": "Senior Vice President of Clinical Development", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bo  Kara", "title": "Senior VP and Head of Pharmaceutical Development & CMC", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.9, "open": 2.89, "dayLow": 2.8048, "dayHigh": 2.93, "regularMarketPreviousClose": 2.9, "regularMarketOpen": 2.89, "regularMarketDayLow": 2.8048, "regularMarketDayHigh": 2.93, "forwardPE": -80.17942, "volume": 1166530, "regularMarketVolume": 1166530, "averageVolume": 950460, "averageVolume10days": 1492190, "averageDailyVolume10Day": 1492190, "bid": 2.82, "ask": 2.9, "bidSize": 200, "askSize": 100, "marketCap": 443717536, "fiftyTwoWeekLow": 2.525, "fiftyTwoWeekHigh": 5.02, "priceToSalesTrailing12Months": 443.71753, "fiftyDayAverage": 3.6375, "twoHundredDayAverage": 3.755825, "currency": "USD", "enterpriseValue": 2144741120, "floatShares": 489934312, "sharesOutstanding": 155146000, "sharesShort": 8032628, "sharesShortPriorMonth": 6631324, "sharesShortPreviousMonthDate": 1732838400, "dateShortInterest": 1735603200, "sharesPercentSharesOut": 0.051799998, "heldPercentInsiders": 0.01017, "heldPercentInstitutions": 0.70587, "shortRatio": 8.42, "shortPercentOfFloat": 0.061300002, "impliedSharesOutstanding": 140243008, "bookValue": 0.469, "priceToBook": 6.0980806, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -45316000, "trailingEps": -0.3, "forwardEps": -0.03, "enterpriseToRevenue": 2144.741, "enterpriseToEbitda": -57.23, "52WeekChange": -0.03814262, "SandP52WeekChange": 0.22408533, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "MREO", "underlyingSymbol": "MREO", "shortName": "Mereo BioPharma Group plc", "longName": "Mereo BioPharma Group plc", "firstTradeDateEpochUtc": 1556112600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "2bb59234-2dd4-3418-a5f3-ada28f11788c", "messageBoardId": "finmb_307970474", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.86, "targetHighPrice": 10.007544, "targetLowPrice": 6.004526, "targetMeanPrice": 7.4767604, "targetMedianPrice": 6.981554, "recommendationMean": 1.14286, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 80522000, "totalCashPerShare": 0.104, "ebitda": -37476000, "totalDebt": 6681000, "quickRatio": 5.834, "currentRatio": 6.104, "totalRevenue": 1000000, "debtToEquity": 9.211, "revenuePerShare": 0.007, "returnOnAssets": -0.3065, "returnOnEquity": -0.73640996, "grossProfits": 1273000, "freeCashflow": -20088750, "operatingCashflow": -30203000, "grossMargins": 1.273, "operatingMargins": -38.066, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-18"}]